Author(s): Isnin Anang Marhana, Andri Dwi Wahyudi, Alfian Nur Rosyid


DOI: 10.52711/0974-360X.2024.00052   

Address: Isnin Anang Marhana*, Andri Dwi Wahyudi, Alfian Nur Rosyid
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Airlangga University, Surabaya, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
*Corresponding Author

Published In:   Volume - 17,      Issue - 1,     Year - 2024

Background: The terminal stage of cancer with distant metastasis often concurrent with malignant pleural effusion (MPE), which is the complication in lung cancer cases. Pleurodesis was performed by inserting a sclerosing agent through the thoracal drain after the pleural fluid was evacuated. Objective: to determine whether rapid pleurodesis is more efficient and effective than the standard procedure pleurodesis in MPE patients. Methods: This experimental study using randomized posttest-only control group design and divided into two groups (standard procedure pleurodesis group and rapid pleurodesis group). All of the samples were inpatient with MPE requiring pleurodesis and eligible with the inclusion criteria as samples. Pleurodesis procedure was performed by inserting a sclerosing agent through the thoracic drain after fluid well evacuated using talc slurry, and evaluated 1 month after pleurodesis procedure. All data were analyzed using SPSS software. Results: A total of 25 samples were included in this study. Our study suggests that standard procedure findings were the same as the rapid group (90.9% vs. 81.81%; p = 0.30). But the rapid group was had a shorter length of stay compared with the standard group (24.62 vs. 29.08 days; p = 0.42) and cheaper (USD 1,700 vs. USD 1,876; p = 0.98). Pain and fever were common complications in both groups. Conclusions: Rapid and standard pleurodesis groups showed the same efficiency and effectivity rates in treating MPE patients. However, the rapid pleurodesis group has a shorter length of stay and cheaper, but there was no statistically difference.

Cite this article:
Isnin Anang Marhana, Andri Dwi Wahyudi, Alfian Nur Rosyid. Comparison between Rapid and Standard procedure Pleurodesis outcome in Malignant Pleural Effusion. Research Journal of Pharmacy and Technology. 2024; 17(1):333-9. doi: 10.52711/0974-360X.2024.00052

Isnin Anang Marhana, Andri Dwi Wahyudi, Alfian Nur Rosyid. Comparison between Rapid and Standard procedure Pleurodesis outcome in Malignant Pleural Effusion. Research Journal of Pharmacy and Technology. 2024; 17(1):333-9. doi: 10.52711/0974-360X.2024.00052   Available on:

1.    Huang J, Ngai CH, Deng Y, Tin MS, Lok V, Zhang L, Yuan J, Xu W, Zheng ZJ, Wong MCS. Cancer Incidence and Mortality in Asian Countries: A Trend Analysis. Cancer Control. 2022; 29: 10732748221095955. doi: 10.1177/10732748221095955.
2.    The Global Cancer Observatory. Lung source: Globocan 2018. Glob Cancer Obs. 2018; 876: 1-2.
3.    Priya S, Ramamurthy B. Lung Cancer Detection using Image Processing Technique. Research J. Pharm. and Tech. 2018; 11(5): 2045-2049. doi: 10.5958/0974-360X.2018.00379.7.
4.    Pandian R, Kumari L. C T Image for Lung Cancer Identification. Research J. Pharm. and Tech. 2016; 9(12): 2359-2361. doi: 10.5958/0974-360X.2016.00471.6.
5.    World Health Organization. Globocan 2020. Int Agency Res. 2020.
6.    Fadholly A, Ansori ANM, Utomo B. Anticancer Effect of Naringin on Human Colon Cancer (WiDr Cells): In Vitro Study. Research Journal of Pharmacy and Technology. 2022; 15(2): 885-888. DOI: 10.52711/0974-360X.2022.00148.
7.    Lemjabbar-Alaoui H, Hassan OU, Yang YW, Buchanan P. Lung cancer: Biology and treatment options. Biochim Biophys Acta. 2015; 1856(2): 189-210. doi: 10.1016/j.bbcan.2015.08.002.
8.    Anggaraditya PB, Adiputra PAT, Widiana IK. EGFR Nanovaccine in Lung Cancer Treatment. Bali Med J. 2019; 8(3): 844. doi: 10.15562/bmj.v8i3.1494.
9.    Iqbalawaty I, Yani M, Machillah N, Fajriah F, Abdullah A, Ilzana TM, Khaled TM, Purnamasari D. Diagnostic Test of Thorax Computed Tomography Scanning in Lung Tumors Against Cytopathological Results at Zainoel Abidin Hospital, Banda Aceh, Indonesia period June - August 2018. Bali Med J. 2019; 8(3): 930. doi: 10.15562/bmj.v8i3.1690.
10.    Nag MK, Patel S, Panik R, Shrivastava S, Daharwal SJ, Singh MR, Singh D. Lung Cancer Targeting: A Review. Research J. Pharm. and Tech. 2013; 6(11): 1302-1306.
11.    Jain MS, Barhate SD, Shimpi RD. Mobocertinib is an Oral kinase inhibitor targeted against EGFR and used in the treatment of Non-small cell Lung cancer: A Review. Asian Journal of Pharmaceutical Research. 2022; 12(2): 179-2. doi: 10.52711/2231-5691.2022.00029.
12.    Joubert KD, Okusanya OT, Mazur S, Ryan JP, Ekeke CN, Schuchert MJ, Soloff AC, Dhupar R. Prognostic Difference of Pleural versus Distant Metastasis after Surgery for Lung Cancer. J Clin Med. 2021; 10(21): 4846. doi: 10.3390/jcm10214846.
13.    Sari S, Andayani TM, Endarti D, Widayati K. Health-Related Quality of Life in Non-Small Cell Lung Cancer (NSCLC) Patients with Mutation of Epidermal Growth Factor Receptor (EGFR) in Indonesia. Research J. Pharm. and Tech. 2020; 13(1): 443-447. doi: 10.5958/0974-360X.2020.00086.4.
14.    Yablonskii P, Nefedov A, Arseniev A, Kozak A, Mortada M, Patsyuk A. Non-small cell lung cancer, pleural effusion and carcinomatosis: always a criterion of inoperability?. AME Med J. 2020; 5: 1-8. doi: 10.21037/amj.2020.02.07.
15.    Hashempour R, Aryannia A, Mehrjerdian M, Baniaghil SS, Rezaie A, Alipoor R. The Concentration of Interleukin-27 in the pleural fluid of patients with exudative pleural effusion and its diagnostic value in differentiating between benign and malignant pleural effusion. Bali Med J. 2018; 7(1): 205-209. doi: 0.15562/bmj.v7i1.926.
16.    Mallow C, Hayes M, Semaan R, Smith T, Hales R, Brower R, Yarmus L. Minimally Invasive Palliative Interventions in Advanced Lung Cancer. Expert Rev Respir Med. 2018; 12(7): 605-614. doi: 10.1080/17476348.2018.1486709.
17.    Foo CT, Pulimood T, Knolle M, Marciniak SJ, Herre J. Day case rapid pleurodesis in malignant pleural effusion. 2021; 58(65): OA235. doi: 10.1183/13993003.
18.    Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ; BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010; 65(2): ii32-40. doi: 10.1136/thx.2010.136994.
19.    Abrão FC, de Abreu IRLB, de Oliveira MC, Viana GG, Pompa Filho JFS, Younes RN, Negri EM. Prognostic factors of recurrence of malignant pleural effusion: what is the role of neoplasia progression? J Thorac Dis. 2020; 12(3): 813-822. doi: 10.21037/jtd.2020.01.13.
20.    Awadallah SF, Bowling MR, Sharma N, Mohan A. Malignant pleural effusion and cancer of unknown primary site: a review of literature. Ann Transl Med. 2019; 7(15): 353. doi: 10.21037/atm.2019.06.33.
21.    Dwivedi N, Dwivedi B, Mishra S, Shukla Y. Lupeol Induced Apoptosis in Human Lung Cancer Cell Line: A Flow Cytometry Study. Research Journal of Pharmacology and Pharmacodynamics. 2014; 6(4): 197-203.
22.    Abdulla HAK, Mustafa AH, Al-Mayah QS. Association of Different Variants in ERCC2 Gene with Susceptibility to Lung Cancer. Research J. Pharm. and Tech. 2018; 11(3): 1078-1082. doi: 10.5958/0974-360X.2018.00201.9.
23.    Chalmers AW, Patel SB, Akerley W. Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: A new standard of care?. J Thorac Dis. 2018; 10(3): 1198–1200. doi: 10.21037/jtd.2018.01.160.
24.    Burgess JT, Rose M, Boucher D, Plowman J, Molloy C, Fisher M, O'Leary C, Richard DJ, O'Byrne KJ, Bolderson E. The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer. Front Oncol. 2020; 10: 1256. doi: 10.3389/fonc.2020.01256.
25.    Taufik F, Susanto A, Simarmata E, Faisal H, Jusuf A. Lung cancer risk factors. UIP. 2017. 11-12.
26.    Kim AS, Ko HJ, Kwon JH, Lee JM. Exposure to Secondhand Smoke and Risk of Cancer in Never Smokers: A Meta-Analysis of Epidemiologic Studies. Int J Environ Res Public Health. 2018; 15(9): 1981. doi: 10.3390/ijerph15091981.
27.    Bokadia Gs, Brundha MP, Ariga P. Current Knowledge about lung cancer Amongmiddleaged Non Medical males A Questionnaire Based Survey. Research J. Pharm. and Tech. 2018; 11(6): 2565-2568. doi: 10.5958/0974-360X.2018.00474.2.
28.    Chanda C. Role of Inflammatory Cytokines during Lung Cancer Progression: A Review. Research J. Pharm. and Tech. 2018; 11(11): 5163-5165 doi: 10.5958/0974-360X.2018.00943.5.
29.    Septiani A, Dewi PPAP, Widyoningroem A, Sensusiati AD, Yamin M. The relationship between Epidermal Growth Factor Receptor (EGFR) mutation and computed tomography findings in lung adenocarcinoma. Bali Med J. 2019; 8(2): 602-5.
30.    Dubin S, Griffin D. Lung Cancer in Non-Smokers. Mo Med. 2020; 117(4): 375-379. PMID: 32848276.
31.    Woo CG, Son SM, Han HS, Lee KH, Choe KH, An JY, Lee KM, Lim YH, Lee HC, Lee OJ. Diagnostic benefits of the combined use of liquid-based cytology, cell block, carcinoembryonic antigen immunocytochemistry in malignant pleural effusion. J Thorac Dis. 2018; 10(8): 4931–4939. doi: 10.21037/jtd.2018.07.139.
32.    Farrag MA, Diab HS, Abd Al Aziz Taha MR. Evaluation of rapid pleurodesis technique in patients with malignant pleural effusion. Egypt J Bronchol. 2019; 13(3): 377–81.
33.    Krishna R, Rudrappa M. Pleural Effusion. 2022 Jul 30 In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022. PMID: 28846252.
34.    Shehata SM, Sileem AE, El-Fakharany KM. Pleural fluid CRP, LDH, and pH as predictors of successful pleurodesis in malignant pleural effusions. Egypt J Chest Dis Tuberc. 2015; 64(3): 593–9. doi: 10.1016/j.ejcdt.2015.05.003.
35.    Mercer RM, Corcoran JP, Porcel JM, Rahman NM, Psallidas I. Interpreting pleural fluid results. Clin Med (Lond). 2019; 19(3): 213-217. doi: 10.7861/clinmedicine.19-3-213.
36.    Poggiali E, Zaino D, Immovilli P, Rovero L, Losi G, Dacrema A, Nuccetelli M, Vadacca GB, Guidetti D, Vercelli A, Magnacavallo A, Bernardini S, Terracciano C. Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients. Clin Chim Acta. 2020; 509: 135-138. doi: 10.1016/j.cca.2020.06.012.
37.    Yildirim E, Dural K, Yazkan R, Zengin N, Yildirim D, Gunal N, Sakinci U. Rapid pleurodesis in symptomatic malignant pleural effusion. Eur J Cardiothorac Surg. 2005; 27(1): 19-22. doi: 10.1016/j.ejcts.2004.08.034.
38.    Magdy KM, Hieba EG. Outcome of ultrasound-guided, single session pleurodesis in malignant pleural effusion. Egypt J Bronchol. 2020; 14(1): 1-7. doi: 10.1186/s43168-020-00009-y.
39.    Ali M, Surani S. Pleurodesis. 2022 Jul 25 In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. PMID: 32809520.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

56th percentile
Powered by  Scopus

SCImago Journal & Country Rank

Recent Articles


Not Available